-41.6%
ORCL vs MRNA
+755.5%
-797.1%
-53.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | -3.4% | +2.1% | -1.3% |
| 7D | +8.0% | -12.1% | +20.1% | +8.3% |
| 30D | -4.0% | -1.3% | -2.7% | -4.0% |
| 3M | -19.5% | +250.9% | -270.4% | -23.0% |
| 6M | -33.5% | +343.0% | -376.5% | -38.3% |
| YTD | -34.8% | +657.4% | -692.3% | -43.9% |
| 1Y | -41.6% | +794.9% | -836.5% | -50.7% |
| All | -41.6% | +755.5% | -797.1% | -50.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling